Free Trial

Guardant Health, Inc. (NASDAQ:GH) Stock Now Rated "Moderate Buy" by Wall Street Analysts

Guardant Health logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts rate Guardant Health a “Moderate Buy”: Of 26 covering brokerages, 24 recommend buying, one rates it a strong buy, and one recommends selling. The average 12-month price target is $190.88.
  • Quarterly results beat expectations: Guardant reported a loss of $0.29 per share versus analysts’ expected loss of $0.75, while revenue of $360.98 million exceeded estimates and grew 36.1% year over year.
  • Insiders sold shares as institutions increased holdings: Insiders sold 53,039 shares worth about $9.1 million over 90 days, while institutional investors owned 92.6% of the stock.
  • Interested in Guardant Health? Here are five stocks we like better.

Shares of Guardant Health, Inc. (NASDAQ:GH - Get Free Report) have been given a consensus rating of "Moderate Buy" by the twenty-six brokerages that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, twenty-four have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $190.88.

A number of equities research analysts have recently weighed in on GH shares. Stifel Nicolaus raised their price target on Guardant Health from $130.00 to $180.00 and gave the stock a "buy" rating in a research note on Friday, July 31st. Royal Bank Of Canada boosted their price target on Guardant Health from $185.00 to $200.00 and gave the company an "outperform" rating in a research note on Friday, July 31st. Piper Sandler lowered their price target on Guardant Health from $193.00 to $190.00 and set an "overweight" rating for the company in a research note on Tuesday, November 10th. Sanford C. Bernstein restated an "outperform" rating and issued a $210.00 price objective on shares of Guardant Health in a report on Thursday, September 10th. Finally, Guggenheim raised their price objective on shares of Guardant Health from $190.00 to $200.00 and gave the company a "buy" rating in a research report on Thursday, October 1st.

Read Our Latest Stock Report on Guardant Health

Guardant Health Price Performance

Shares of NASDAQ:GH opened at $151.70 on Monday. The firm has a fifty day moving average of $168.64 and a two-hundred day moving average of $132.99. The firm has a market capitalization of $20.52 billion, a P/E ratio of -41.22 and a beta of 1.67. Guardant Health has a 12-month low of $74.55 and a 12-month high of $191.05.

Guardant Health (NASDAQ:GH - Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.46. The company had revenue of $360.98 million for the quarter, compared to analysts' expectations of $350.72 million. During the same quarter in the prior year, the firm earned ($0.74) earnings per share. The company's revenue was up 36.1% on a year-over-year basis. Equities research analysts expect that Guardant Health will post -3.08 earnings per share for the current fiscal year.

Insider Buying and Selling at Guardant Health

In other news, Director Alex M. Azar II sold 826 shares of the firm's stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $175.00, for a total transaction of $144,550.00. Following the transaction, the director owned 825 shares in the company, valued at approximately $144,375. This trade represents a 50.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Steve E. Krognes sold 6,674 shares of the firm's stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $175.74, for a total transaction of $1,172,888.76. Following the transaction, the director owned 7,906 shares in the company, valued at $1,389,400.44. This represents a 45.78% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 53,039 shares of company stock valued at $9,088,877. 5.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Guardant Health

A number of large investors have recently bought and sold shares of the business. Entropy Technologies LP increased its position in Guardant Health by 712.9% during the third quarter. Entropy Technologies LP now owns 44,393 shares of the company's stock worth $7,918,000 after buying an additional 38,932 shares during the last quarter. Jump Financial LLC raised its holdings in Guardant Health by 106.4% during the third quarter. Jump Financial LLC now owns 149,000 shares of the company's stock valued at $26,576,000 after buying an additional 76,818 shares in the last quarter. Pathstone Holdings LLC raised its holdings in Guardant Health by 0.8% during the third quarter. Pathstone Holdings LLC now owns 52,965 shares of the company's stock valued at $9,363,000 after buying an additional 397 shares in the last quarter. Marshall Wace LLP lifted its position in shares of Guardant Health by 56.1% in the third quarter. Marshall Wace LLP now owns 288,980 shares of the company's stock worth $51,542,000 after buying an additional 103,830 shares during the last quarter. Finally, Caxton Associates LLP lifted its position in shares of Guardant Health by 21.5% in the third quarter. Caxton Associates LLP now owns 24,455 shares of the company's stock worth $4,362,000 after buying an additional 4,328 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors.

Guardant Health Company Profile

(Get Free Report)

Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring. Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.

See Also

Analyst Recommendations for Guardant Health (NASDAQ:GH)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Guardant Health Right Now?

Before you consider Guardant Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.

While Guardant Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines